Trials and Fibrillations with Dr John Mandrola

 
 

Trials and Fibrillations with Dr John Mandrola

  • Overdiagnosis Only a Matter of Time With ECG Watches An Apple Watch with an ECG reader may be fun for specific tasks, but it's fantasy to think it will improve health outcomes, according to this electrophysiologist.
  • AHA Better Patient Decisions: A Destination Within Reach A study showing that a comprehensive decision aid could help patients make treatment choices in line with their values is Dr Mandrola’s favorite trial of AHA 2017.
  • AHA What if Quality Measures Increased Mortality? Dr Mandrola reports on a provocative study showing that reducing readmissions for heart failure associates with higher mortality.
  • AHA Ushering in a New Era of Disease Prediction Dr Mandrola attended a young investigators award session and reports on the future of risk prediction--which means knowing our DNA.
  • TCT Seven Reasons New Data on Watchman Are Not Persuasive PREVAIL 5-year data and a patient-level meta-analysis nudge the Watchman left atrial appendage device to meeting noninferiority, but the devil is in the details, notes Dr Mandrola.
  • AHA Mandrola Previews AHA 2017 The American Heart Association Scientific Sessions begin in Anaheim November 11. Learn which updates Dr Mandrola is most looking forward to.
  • Coronary Stents Humbled Yet Again in Stable CAD ORBITA, a sham-control PCI trial, found no angina benefit for stents in patients with stable CAD. Ten years after COURAGE, it's high time cardiologists treat patients, not lesions, pleads Dr Mandrola.
  • TCT Will I Feel Better? QoL Outcomes Make the Big Stage at TCT A quality-of-life substudy of a trial comparing coronary stenting and bypass surgery could herald a new era of truly patient-centered decision-making, hopes Dr Mandrola.
  • We Need Consistency, Not Complacency, to Improve Public Health Obesity has been normalized to become the problem clinicians don't see and therefore don't treat, but recent data showing that one in five kids and teens are obese should shock us into action, says Dr Mandrola.
  • Positive Results for PFO Closure Come With Caveats Three studies give PFO closure in cryptogenic stroke a boost, but patient selection is critical, and let's not forget about direct oral anticoagulants, cautions Dr Mandrola.
  • Pacemaker Hacking: Good TV Plot, but Not Worth Alarming Patients A cybersecurity vulnerability leaves some pacemakers susceptible to hacking, but this remote possibility does not warrant the risk of the fix and unnecessarily worrying patients, argues Dr Mandrola.
  • ESC FOURIER: Post Hoc Analysis Doesn't Move the Needle Yes, PCSK9 inhibitors can drop LDL-C levels very, very low, but Dr John Mandrola is not yet convinced of their viability in the real world after the presentation of a FOURIER study at ESC 2017.
  • ESC COMPASS: Don't Pop the Champagne Yet Dr John Mandrola is not convinced that the COMPASS trial findings warrant adding low-dose of rivaroxaban twice daily on top of aspirin to an already pill-burdened patient population.
  • ESC CASTLE-AF: Does It Change the World of AF Ablation? Dr John Mandrola discusses the CASTLE-AF trial, the reaction from the EP community, and some of his concerns.
  • ESC Quick Thoughts on the CANTOS Trial Dr John Mandrola offers his first reactions to the landmark CANTOS trial presentation at the ESC meeting.
  • Statins After Stroke: Don't Take as Gospel Dr Mandrola challenges the orthodoxy of mandatory statins in patients who present with stroke (or TIA) because the patients he sees often don't resemble those in the clinical trials.
  • Enough With the Coffee Research and Other Distractions Observational studies on coffee, chocolate (name the food) garner headlines but frustrate Dr Mandrola, who wishes that our attention and research dollars were better spent.
  • Time to Nip Routine Stress Tests After ED Visits in the Bud Stress tests in low-risk patients with chest pain may help rack up RVUs, but they’re unlikely to help patients, argues Dr Mandrola.
  • EHRA Real-World Data on Left Atrial Appendage Closure Does Not Reassure Registry data from EHRA EUROPACE-CARDISTIM 2017 raise concerns that device complications and the need for antithrombotic therapy may limit any potential benefit for left atrial appendage closure.
  • EHRA The Danger of AF Without Symptoms Atrial fibrillation symptoms are bothersome and cause anxiety, but they could be a blessing in disguise. A presentation at EHRA finds that patients without symptoms fare worse in terms of clinical events.